Zegalogue Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10442847 ZEALAND PHARMA Glucagon analogues
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11795204 ZEALAND PHARMA Glucagon analogues
Jan, 2034

(9 years from now)



Zegalogue is a drug owned by Zealand Pharma Us Inc. It is used for managing low blood sugar levels in diabetic patients. Zegalogue uses Dasiglucagon Hydrochloride as an active ingredient. Zegalogue was launched by Zealand Pharma in 2021. It is is available in solution form for subcutaneous use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 03, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient

NCE-1 date: 22 March, 2025

Market Authorisation Date: 22 March, 2021

Treatment: Method of treating diabetic hypoglycemia

Dosage: SOLUTION

More Information on Dosage

ZEGALOGUE family patents

Family Patents